TY - JOUR
T1 - Atrial fibrillation inducibility during cavotricuspid isthmus-dependent atrial flutter ablation as a predictor of clinical atrial fibrillation. A meta-analysis
AU - Romero, Jorge
AU - Diaz, Juan Carlos
AU - Di Biase, Luigi
AU - Kumar, Saurabh
AU - Briceno, David
AU - Tedrow, Usha B.
AU - Valencia, Carolina R.
AU - Baldinger, Samuel H.
AU - Koplan, Bruce
AU - Epstein, Laurence M.
AU - John, Roy
AU - Michaud, Gregory F.
AU - Stevenson, William G.
N1 - Funding Information:
Dr Di Biase is a consultant for Biosense Webster, Boston Scientific, and St. Jude Medical and has received speaker honoraria/travel from Medtronic, Atricure, EPiEP, and Biotronik. Dr. Kumar is a recipient of the Neil Hamilton Fairley Overseas Research scholarship co-funded by the National Health and Medical Research Council and the National Heart Foundation of Australia; and the Bushell Travelling Fellowship funded by the Royal Australasian College of Physicians and the Postdoctoral Research Fellowship by the American Heart Association. Dr. Tedrow receives consulting fees/honoraria from Boston Scientific Corp. and St. Jude Medical and research funding from Biosense Webster, Inc., and St. Jude Medical. Dr. John receives consulting fees/honoraria from St. Jude Medical. Dr. Michaud receives consulting fees/honoraria from Boston Scientific Corp., Medtronic, Inc., and St. Jude Medical, and research funding from Boston Scientific Corp. and Biosense Webster, Inc. Dr. Stevenson is co-holder of a patent for needle ablation that is consigned to Brigham and Women’s Hospital. The remaining authors have no disclosures.
Publisher Copyright:
© 2017, Springer Science+Business Media New York.
PY - 2017/4/1
Y1 - 2017/4/1
N2 - Background: Atrial fibrillation (AF) and cavotricuspid isthmus (CTI)-dependent atrial flutter (AFL) are two separate entities that coexist in a significant percentage of patients. We sought to investigate whether AF inducibility during CTI AFL ablation predicted the occurrence of AF at follow-up after successful AFL ablation. Methods: A systemic review of Medline, Cochrane, and Embase was done for all the clinical studies in which assessment of AF inducibility in patients undergoing ablation for CTI AFL was performed. Given the low heterogeneity (i.e., I2 <25), we used a fixed effect model for our analysis. Results: A total of 10 studies (4 prospective and 6 retrospective) with a total of 1299 patients (male, 73%; mean age 59 ± 11 years) fulfilled the inclusion criteria. During a mean follow-up period of 23 ± 7.6 months, 407 patients (31%) developed AF during AFL ablation. The overall incidence for new-onset AF during follow-up was 29% (47% in the group with inducible AF vs. 21% in the non-inducible group). The odds ratio (OR) for developing AF after AFL ablation in patients with AF inducibility for all studies combined was 3.72, 95% CI 2.83–4.89 [prospective studies (OR 5.52, 95% CI 3.23–9.41) vs. retrospective studies (OR 3.23, 95% CI 2.35–4.45)]. Conclusions: Although ablation for CTI AFL is highly effective, AF continues to be a long-term risk for individuals undergoing this procedure. AF induced by pacing protocols in patients undergoing CTI AFL predicts for future AF. Inducible AF is a clinically relevant finding that may help guide decisions for long-term anticoagulation after successful typical AFL ablation especially in patients with elevated CHADS-VASc scores (≥2) and in considering prophylactic PVI during CTI AFL ablation.
AB - Background: Atrial fibrillation (AF) and cavotricuspid isthmus (CTI)-dependent atrial flutter (AFL) are two separate entities that coexist in a significant percentage of patients. We sought to investigate whether AF inducibility during CTI AFL ablation predicted the occurrence of AF at follow-up after successful AFL ablation. Methods: A systemic review of Medline, Cochrane, and Embase was done for all the clinical studies in which assessment of AF inducibility in patients undergoing ablation for CTI AFL was performed. Given the low heterogeneity (i.e., I2 <25), we used a fixed effect model for our analysis. Results: A total of 10 studies (4 prospective and 6 retrospective) with a total of 1299 patients (male, 73%; mean age 59 ± 11 years) fulfilled the inclusion criteria. During a mean follow-up period of 23 ± 7.6 months, 407 patients (31%) developed AF during AFL ablation. The overall incidence for new-onset AF during follow-up was 29% (47% in the group with inducible AF vs. 21% in the non-inducible group). The odds ratio (OR) for developing AF after AFL ablation in patients with AF inducibility for all studies combined was 3.72, 95% CI 2.83–4.89 [prospective studies (OR 5.52, 95% CI 3.23–9.41) vs. retrospective studies (OR 3.23, 95% CI 2.35–4.45)]. Conclusions: Although ablation for CTI AFL is highly effective, AF continues to be a long-term risk for individuals undergoing this procedure. AF induced by pacing protocols in patients undergoing CTI AFL predicts for future AF. Inducible AF is a clinically relevant finding that may help guide decisions for long-term anticoagulation after successful typical AFL ablation especially in patients with elevated CHADS-VASc scores (≥2) and in considering prophylactic PVI during CTI AFL ablation.
KW - AF inducibility
KW - Atrial fibrillation
KW - Atrial flutter
KW - Cavotricuspid isthmus atrial flutter
UR - http://www.scopus.com/inward/record.url?scp=85008705397&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85008705397&partnerID=8YFLogxK
U2 - 10.1007/s10840-016-0211-9
DO - 10.1007/s10840-016-0211-9
M3 - Article
C2 - 28070875
AN - SCOPUS:85008705397
SN - 1383-875X
VL - 48
SP - 307
EP - 315
JO - Journal of Interventional Cardiac Electrophysiology
JF - Journal of Interventional Cardiac Electrophysiology
IS - 3
ER -